Physician profile
Suzanne E Runge
NPI 1245663038
$2,439.03
in general payments reported to CMS, 2019-2025
26 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $595 · 2022: $609 · 2023: $577 · 2024: $326 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $376.24 | 2021-2025 | Breztri, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $276.56 | 2021-2022 | |
| Pfizer INC. | $162.42 | 2021-2025 | |
| Abbott Laboratories | $155.71 | 2021-2025 | Freestyle Libre 3, Amplatzer Amulet |
| Janssen Pharmaceuticals, INC | $140.17 | 2021-2023 | Xarelto |
| Abbvie INC. | $133.30 | 2023-2025 | |
| Amgen INC. | $132.34 | 2021-2024 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $130.61 | 2022-2025 | Mounjaro, Jardiance, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $125.07 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $115.78 | 2021-2023 | |
| Glaxosmithkline, LLC. | $109.88 | 2022-2024 | Trelegy Ellipta |
| Exact Sciences Corporation | $92.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.06 | 2022-2025 | Caplyta |
| Amarin Pharma, INC. | $58.21 | 2021 | |
| Boston Scientific Corporation | $57.80 | 2022-2024 | Lux-Dx Insertable Cardiac Monitor |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.11 | 2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $48.79 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.67 | 2022 | |
| Almatica Pharma LLC | $24.69 | 2023 | Loreev Xr, Sertraline Hcl, Gralise |
| Ibsa Pharma INC. | $21.64 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.24 | 2021 | |
| Astellas Pharma US INC | $19.33 | 2023 | Veozah |
| Merck Sharp & Dohme LLC | $17.61 | 2022 | |
| Sonex Health, INC. | $17.42 | 2025 | Sx-One Microknife |
| Philips North America LLC | $15.23 | 2023 | |
| Novo Nordisk INC | $12.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Runge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.